FDA OKs mipomersen for homozygous familial hypercholesterolemia

01/29/2013 | Bloomberg Businessweek · Fox Business

Isis Pharmaceuticals and Sanofi unit Genzyme obtained FDA approval to market Kynamro, or mipomersen, as an add-on treatment to lipid-lowering drugs and diet for patients with homozygous familial hypercholesterolemia. Due to risks of liver problems, the once-weekly injectable drug will carry a boxed warning. The approval triggers the payment of a $25 million milestone fee from Genzyme to Isis.

View Full Article in:

Bloomberg Businessweek · Fox Business

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ